Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Is The Anticipated Size Of The Viral And Non-Viral Vector Manufacturing Market Over The Five-Year Period 2025–2029?
The viral and non-viral vector manufacturing market size has seen rapid growth over recent years. It is forecast to increase from $8.67 billion in 2024 to $10.28 billion in 2025, achieving a compound annual growth rate (CAGR) of 18.5%. This historical expansion can be linked to the growing occurrence of genetic disorders, progress in biotechnology, increased investments in gene therapy research, heightened awareness of personalized medicine, and supportive regulations for gene therapy development.
The viral and non-viral vector manufacturing market size is poised for rapid and accelerating expansion in the coming years. It is projected to reach $22.01 billion by 2029, driven by a compound annual growth rate (CAGR) of 21.0%. This growth throughout the forecast period is attributable to increasing demand for gene therapies, broadening applications in rare disease treatment, rising investments in biomanufacturing infrastructure, and the expanding adoption of precision medicine. Key trends anticipated during this period encompass the development of next-generation viral vectors, a greater utilization of CRISPR or cas9 technology in vector manufacturing, a focus on scalable and cost-effective manufacturing processes, the increasing uptake of non-viral vectors, and advancements in cell and gene therapy manufacturing technologies.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12570&type=smp
Which Factors And Drivers Are Influencing The Viral And Non-Viral Vector Manufacturing Market In 2025?
The rising occurrence of genetic disorders is projected to fuel the expansion of the viral and non-viral vector manufacturing markets. Genetic disorders are conditions resulting entirely or partly from a deviation in the typical DNA sequence. Viral vectors operate by delivering therapeutic genes to target cells, thereby replacing or supplementing the defective genes responsible for these disorders. Conversely, non-viral vectors are commonly utilized in ex vivo gene therapy approaches, which involve genetically modifying cells outside the body before reinfusion into the patient. For example, the International Diabetes Federation, a Belgium-based organization, stated in June 2022 that the global prevalence of diabetes had risen to 10.5%. Over half (44.7%) of those affected were still undiagnosed, and by 2045, around 783 million adults, equivalent to one in eight people, are anticipated to have diabetes. Thus, the increasing incidence of genetic disorders acts as a significant driver for the growth of the viral and non-viral vector manufacturing market.
How Is The Viral And Non-Viral Vector Manufacturing Market Segmented?
The viral and non-viral vector manufacturingmarket covered in this report is segmented –
1) By Vector Type: Viral Vector; Non-Viral Vector
2) By Disease: Cancer; Genetic Disease; Infectious Disease; Cardiovascular Disease; Other Diseases
3) By Application: Gene Therapy; Vaccinology; Cell Therapy; Other Applications
Subsegments:
1) By Viral Vector: Adenoviral Vectors; Lentiviral Vectors; AAV (Adeno-Associated Virus) Vectors; Retroviral Vectors; Other Viral Vectors
2) By Non-Viral Vector: Plasmid DNA; Lipid-Based Vectors; Nanoparticles; Electroporation-Based Vectors; Other Non-Viral Vectors
What Key Innovation Trends Are Fueling Advancements In The Viral And Non-Viral Vector Manufacturing Market?
Technological advancements are a crucial trend gaining prominence in the viral and non-viral vector manufacturing markets. Major companies operating in these markets are developing technologically advanced solutions to sustain their competitive standing. For instance, in August 2022, Merck KGaA, a Germany-based science and technology company, launched the VirusExpress 293 Adeno-Associated Virus (AAV) Production Platform. This positions them as one of the pioneering Contract development and manufacturing organizations and technology creators to offer a comprehensive viral vector manufacturing package, including AAV, Lentiviral, CDMO, CTO, and process development services. Through this innovative platform, biopharmaceutical businesses can reduce the time and expense involved in process development, thereby accelerating their journey to clinical manufacturing.
Which Major Industry Participants Are Leading The Viral And Non-Viral Vector Manufacturing Market Growth?
Major companies operating in the viral and non-viral vector manufacturing market include Novartis AG, Thermo Fisher Scientific Inc., Merck KGaA, FUJIFILM Holdings Corporation, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Lonza Group AG, WuXi AppTec Co Ltd., Catalent Inc., Sartorius AG, Charles River Laboratories Inc., Sarepta Therapeutics Inc., GenScript ProBio Co. Ltd., TAKARA BIO Inc., Oxford BioMedica plc, Beam Therapeutics Inc., Intellia Therapeutics Inc., MaxCyte Inc., Voyager Therapeutics Inc., Genethon, MeiraGTx Holdings plc, Evox Therapeutics Ltd., Entos Pharmaceuticals Inc., LogicBio Therapeutics Inc., bluebird bio Inc., 4D Molecular Therapeutics Inc., Precision NanoSystems Inc., GenSight Biologics S.A., Abeona Therapeutics Inc., Generation Bio Co.
Download The Full Report For Exclusive Market Findings:
Which Region Is Projected To Lead The Viral And Non-Viral Vector Manufacturing Market During The Forecast Period?
North America was the largest region in the viral and non-viral vector manufacturing market in 2024. The regions covered in the viral and non-viral vector manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Request A Customized Version Of The Viral And Non-Viral Vector Manufacturing Market Report:
https://www.thebusinessresearchcompany.com/customise?id=12570&type=smp
Browse Through More Reports Similar to the Global Viral And Non-Viral Vector Manufacturing Market 2025, By The Business Research Company
Viral Vectors And Plasmid Dna Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/viral-vectors-and-plasmid-dna-global-market-report
Vector Control Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/vector-control-global-market-report
Viral Inactivation Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/viral-inactivation-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model